


IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

VALUE DRUG COMPANY	:	CIVIL ACTION
	:	
v.	:	NO. 21-3500
	:	
TAKEDA PHARMACEUTICALS,	:	
U.S.A., INC., <i>et al.</i>	:	

ORDER

AND NOW, this 28th day of February 2023, upon considering Plaintiff's renewed Motion to certify a class (ECF Doc. No. 700), Defendants' Response (ECF Doc. No. 736), Plaintiff's Reply (ECF Doc. No. 759), pre-hearing Memoranda (ECF Doc. Nos. 834, 836), following extensive oral argument, post-hearing Memoranda (ECF Doc. Nos. 869, 870), and for reasons in the accompanying Memorandum, it is **ORDERED**:

1. Plaintiff's Motion (ECF Doc. No. 700) is **DENIED**; and
2. Lead trial counsel shall meaningfully meet and confer so as to allow Defendants, consistent with our January 18, 2023 Order (ECF Doc. No. 751), to file a joint Notice not exceeding five pages on or before **March 10, 2023** identifying the parties' proposal(s) for our continuing progress towards trial including the number of anticipated trial days.



KEARNEY, J.